Vanadium and proteins: Uptake, transport, structure, activity and function

Redox‐Modulation der PTEN‐Phosphataseaktivität durch Wasserstoffperoxid und Bisperoxidovanadium‐Komplexe

“…[24] Um die Affinität [25] und alkalische Phosphatase (K i = 0.6 mm) [26] ]. Daher waren wir interessiert, ob Orthovanadat auch zur Inhibition von PTEN durch bpV-phen beiträgt.…”

In vitro study of the antidiabetic behavior of vanadium compounds

“…In principle the metal ion can bind to these proteins in the oxidation states of +3, +4 and +5. Large numbers of works have been made in this field to clarify the interactions both qualitatively and quantitatively and the results published in numerous review papers [1,3,4,6,8] Binding can occur in metal-protein binary interactions, and in forms of ternary complexes when the carrier ligands also participate in binding.…”

“…14.1±0.5 [57] a Calculated using data from Ref. [48,61] The order of affinity of the three vanadium oxidation states towards human apoTF is therefore: V(III)°>°VO(IV) > V(V), in the presence of carbonate and V(III) ∼ VO(IV) > V(V) in its absence [3]. In one type of complexes vanadium is assumed to bind at the Fe(III)…”

“…Progress in the bioinorganic chemistry of vanadium and the search in the therapeutic applications have been exponential and numerous reviews have been published in recent years [1][2][3][4][5][6][7][8]. Vanadium compounds have been shown to be potentially effective against diabetes, malign tumors including cancer, endemic tropical diseases (such as trypanosomiasis, leishmaniasis and amoebiasis), bacterial infections (tuberculosis and pneumonia) and HIV infections.…”

Vanadyl complexes with dansyl-labelled di-picolinic acid ligands: synthesis, phosphatase inhibition activity and cellular uptake studies

“…5,[7][8][9][10][11][12][13][14] One subset of these inhibitors are metal ions and their complexes including vanadium, zinc, copper and others, which have shown potent inhibition of PTPs in vitro and in vivo. 11,[15][16][17][18][19] In particular, a variety of complexes with both vanadium(IV) and vanadium(V) centres have been developed and characterised for their CBP inhibition properties 7,10,[20][21][22][23][24][25][26][27] including several examples with picolinic acid and its derivatives as ligands. [28][29][30][31][32][33] The potency of these inhibitors against PTPs and lipid phosphatases can be tuned as a function of the ligand, the vanadium coordination number and the oxidation state.…”